LP
CRL icon

Longaeva Partners’s Charles River Laboratories CRL Stock Holding History

Longaeva Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-36,721
Closed -$6.33M – 359
2026
Q1 		$6.33M Buy
+36,721
New +$6.81M 0.23% 98
2025
Q4 		– Sell
-50,000
Closed -$7.82M – 130
2025
Q3 		$7.82M Buy
+50,000
New +$7.94M 1.13% 23

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Longaeva Partners's CRL Position: Q2 2026 in Review

Longaeva Partners sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 36,721 shares — an estimated $6.33M sold.

Longaeva Partners first reported a position in CRL in Q3 2025 and held it in 2 quarters. The position peaked at $7.82M in Q3 2025. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Longaeva Partners reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • Longaeva Partners sold 36,721 Charles River Laboratories shares in Q2 2026, an estimated $6.33M.
  • Longaeva Partners first reported a position in Charles River Laboratories in Q3 2025 and held it in 2 quarters.
  • Longaeva Partners's Charles River Laboratories position peaked at $7.82M in Q3 2025.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.